Latest filing published 03 Jun 2026 for CVRx, Inc..
Michael D. Dale appears in 19 filings between February 19, 2020 and June 3, 2026, across three companies: Abbott Laboratories (15, as SENIOR VICE PRESIDENT), Axogen, Inc. (3, as Chief Executive Officer) and CVRx, Inc. (1, as Director). The record contains no purchase.
The 7 sales, 5 at Abbott Laboratories and 2 at Axogen, Inc., weigh EUR 4,746,433, median EUR 430,730. The largest goes back to July 28, 2021: EUR 1,787,790 at Abbott Laboratories. It is followed by two successive sales at Axogen, Inc.: EUR 1,647,680 on December 9, 2025 and EUR 644,977 on December 10, 2025.
The rest is 11 grants and one option exercise. Four filings fall in the last twelve months, 2 of them sales. The yearly split runs from 5 filings in 2020 and 2021 to a single one in 2026.
Dale has 4, 3 and 3 own market trades within 30 days of colleagues at Abbott Laboratories, in that order, all on the same side. The colleagues, in the same order: Andrea F. Wainer, Charles Brynelsen and Christopher J. Scoggins.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations